Risky Stem-Cell Treatments Come Under F.D.A. Scrutiny — Again

Warning that unapproved stem-cell treatments put patients at risk, the F.D.A. is notifying clinics and manufacturers that flout its rules. DENISE GRADY https://ift.tt/2UfjXIc https://ift.tt/2FXlKJf The New York Times Health Stem Cells, Regulation and Deregulation of Industry April 3, 2019 at 12:00AM